BioAegis Therapeutics Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$22M
- Investors
-
2
BioAegis Therapeutics General Information
Description
Operator of a clinical-stage drug development platform intended to facilitate the treatment of inflammation and infectious diseases. The company's platform specializes in the research and development of drugs to restore plasma gelsolin - innate immunity that provides an immunotherapeutic approach to fighting pathogens, enabling hospitals to begin treatment and result in a high likelihood of successful treatment.
Contact Information
Website
www.bioaegistherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- Commercialization Center for Innovative Technology
- 675 US Highway One
- North Brunswick, NJ 08902
- United States
+1 (973) 000-0000
BioAegis Therapeutics Timeline
BioAegis Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 22-Mar-2022 | $22M | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 8. Later Stage VC (Series C) | 31-Dec-2021 | 0000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 7. Later Stage VC | 07-Oct-2020 | 000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 6. Debt - PPP | 28-Apr-2020 | 000.00 | Completed | Clinical Trials - Phase 2 | ||
| 5. Later Stage VC (Series B) | 01-Aug-2018 | 00.00 | 000.00 | 000.00 | Completed | Clinical Trials - General |
| 4. Grant | 09-Jul-2016 | 000 | 000.00 | Completed | Clinical Trials - General | |
| 3. Later Stage VC | 11-Mar-2016 | 00.00 | 000.00 | 0000 | Completed | Startup |
| 2. Early Stage VC (Series A) | 01-Jan-2015 | $8.04M | $11M | 0000 | Completed | Startup |
| 1. Angel (individual) | 08-Feb-2013 | $3M | $3M | Completed | Startup |
BioAegis Therapeutics Executive Team (15)
BioAegis Therapeutics Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Kris Vinckier | BioAegis Therapeutics | Board Member | 000 0000 |
| Mark DiNubile MD | BioAegis Therapeutics | Chief Medical Officer & Board Member | 000 0000 |
| Susan Levinson Ph.D | BioAegis Therapeutics | Co-Founder, Board Member & Chief Executive Officer | 000 0000 |
BioAegis Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
BioAegis Therapeutics Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| European Investment Fund | Fund of Funds | Minority | 000 0000 | 000000 0 | |
| National Institute Of Allergy and Infectious Diseases | Government | 000 0000 | 000000 0 |